Boscenco, Sonia, Castillon, Venise Jan, Wang, Jamie, Tse, Ethan, Freeman, Samuel S, Bakouny, Ziad, Mohan, Saksham, Guo, X Alex, Walser, River, Song, Junmin, Zambirinis, Constantinos P, Bojmar, Linda, Kotecha, Ritesh R, Hilmi, Marc, May, Michael S, Vitiello, Gerardo A, Janowitz, Tobias, Goncalves, Marcus D, Gangai, Natalie, Lyden, David, Herskovits, Adrianna Z, Iyengar, Puneeth, Jarnigan, William R, Schwartz, Robert E, Sosa, Ramon, Jee, Justin, O’Reilly, Eileen M, Schultz, Nikolaus, Shah, Sohrab P, Park, Wungki, Garrett, John W, Pickhardt, Perry J, Swinburne, Nathaniel C, Reznik, Ed (May 2026) Anatomical dynamics define cancer cachexia subtypes and identify systemic inflammation as a marker of lethal wasting. medRxiv. (Submitted)
![[thumbnail of 10.64898.2026.05.04.26352250.pdf]](https://repository.cshl.edu/style/images/fileicons/application_pdf.png) |
PDF
10.64898.2026.05.04.26352250.pdf - Submitted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (22MB) |
Abstract
Cancer cachexia is a wasting syndrome that remodels the anatomy of the patient. How this remodeling unfolds across tissues, whether it defines distinct disease states, and how these states relate to underlying biology remain unknown. We used longitudinal computed tomography imaging from 4,516 patients to quantify evolution of muscle, adipose, and organs during cachexia. Across two independent institutional cohorts, unsupervised analysis identified three reproducible anatomical subtypes of cachexia, including an inflammatory Type A marked by progressive hepatosplenic enlargement and inferior survival, a Type B dominated by visceral organ atrophy, and a mild Type C. These anatomical subtypes were associated with distinct serological signatures and reflected in molecular phenotypes in tumors and non-cancerous liver tissue, establishing cachexia as discrete anatomical disease states that link whole-body remodeling to systemic and tissue-level biology. This anatomy-first framework for cachexia classification provides a foundation for future patient stratification and development of subtype-specific anti-cachexia therapies.
| Item Type: | Paper |
|---|---|
| Subjects: | diseases & disorders diseases & disorders > nutritional and metabolic diseases diseases & disorders > nutritional and metabolic diseases > cachexia |
| CSHL Authors: | |
| Communities: | CSHL labs > Janowitz lab |
| SWORD Depositor: | CSHL Elements |
| Depositing User: | CSHL Elements |
| Date: | 5 May 2026 |
| Date Deposited: | 01 Jul 2026 14:00 |
| Last Modified: | 01 Jul 2026 14:00 |
| PMCID: | PMC13174764 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/42249 |
Actions (login required)
 |
Administrator's edit/view item |